IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

Application of: LaColla et al. Confirmation No.: 9201

Serial No.: 10/609,298 Art Unit: 1623

Filed: June 27, 2003 Examiner: T. McIntosh III

For: 2' AND 3' NUCLEOSIDE PRODRUGS Attorney Docket No: 11874-016-999

FOR TREATING FLAVIVIRIDAE (CAM: 417451-999016)
INFECTIONS IDX 1017

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,443 and 11/516,928 (the "reference applications"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patents granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference applications in Idenix

Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique
and L' Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at
reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel
021819 frame 0149; and the assignment attached hereto.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date:	Murt 30, 2001	By:	inx Pharmaceunicals Inc.
			Name: Jeen - Pierce Somma doss.
			Position: Chief Executive Officer
		Univ	versita Degli Studi di Cagliari
Date:		By:	
			Name:
			Position:
		Cent	tre National de la Recherche Scientifique
Date:		_ By:	
			Name:
			Position:
		L' U	niversité Montpellier II
Date:		_ By;	
			Name:
			Position:

CNRS No.: 85256-05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaColla et al. Confirmation No.; 9201

Serial No.: 10/609,298 Art Unit: 1623

Filed: June 27, 2003 Examiner: T. McIntosh III

For: 2' AND 3' NUCLEOSIDE PRODRUGS Attorney Docket No: 11874-016-999

FOR TREATING FLAVIVIRIDAE (CAM: 417451-999016)
INFECTIONS IDX 1017

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir-

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi di Caglian, Center National de la Recherche Scientifique and I.* Université Montpellier II (collectively, "owners"), horeby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend buyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,443 and 11/516,928 (the "refrence applications"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patent granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1,321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of figal title stated above.

Ownership of the above-identified application and the reference applications in Idenix

Pharmaceuticals, Inc., Universita Degli Studi di Caglian, Contre National de la Recherche Scientifique
and J. Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at
reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel
021819 frame 0149; and the assignment attached hereto.

LAI-2987126v2

The undersigned hereby confinn that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

		lden	ix Pharmaceuticals, Inc.
Date:		By:	
			Name:
			Position:
		Univ	orsita Degli Studi di Cagliari
Date:	23.03.2009	By:	Quella Lilla Com
	7		Name: If PETTODE
			Name: IL RETTORE Position: (Pasquale Mistretta)
		Cent	re National de 1s Recherche Scientifique
Date:	to become a constraint of and a first Philadelphia areas and a superior and a sup	Ву:	
			Name:
			Position:
		L' U	niversité Montpollier II
Date:		Ву:	
			Name:
			Position:
LA1-798717	76v2		- 2 -

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaColla et al. Confirmation No.: 9201

Serial No.: 10/609.298 Art Unit: 1623

Filed: June 27, 2003 Examiner: T. McIntosh III

For: 2' AND 3' NUCLEOSIDE PRODRUGS Attorney Docket No: 11874-016-999

FOR TREATING FLAVIVIRIDAE (CAM: 417451-999016)
INFECTIONS IDX 1017

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,443 and 11/516,928 (the "reference applications"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patents granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference applications in Idenix
Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique
and L' Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at
reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel
021819 frame 0149; and the assignment attached hereto.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

		Idenix Pharmaceuticals, Inc.	
Date:		By:	
		Name:	
		Position:	
		Universita Degli Studi di Cagliari	
Date:		By:	
		Name:	
		Position:	
Date:	3 O MARS 2009	Centre National de la Recherche Scientifique Directeur de la folitique Industrie By:	elle
Date.		Name: Marc J. LEDOUX Position:	
		L' Université Montpellier II	
Date:		By:	
		Name:	
		Position:	

IDX 1017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaColla et al. Confirmation No · 9201

Serial No.: 10/609.298 Art Unit: 1623

Filed: June 27, 2003 Examiner: T. McIntosh III

2' AND 3' NUCLEOSIDE PRODRUGS Attorney Docket No: 11874-016-999 FOR TREATING FLAVIVIRIDAE (CAM: 417451-999016) INFECTIONS

TERMINAL DISCLAIMER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:

For:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals. Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,443 and 11/516,928 (the "reference applications"). The owners hereby agree that any patent so granted on the aboveidentified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patents granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference applications in Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel 021819 frame 0149; and the assignment attached hereto.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

		Idenix Pharmaceuticals, Inc.
Date:	****	By:
		Name:
		Position:
		Universita Degli Studi di Cagliari
Date:		By:
		Name:
		Position:
		Centre National de la Recherche Scientifique
Date:		By:
		Name:
		Position:
		L' Université Montpellier II
Date:	15/03/2009	By:
	, ,	Name: The During HERIN
		Position: President
		allo 2
		-2-

PATENT ASSIGNMENT AGREEMENT

THIS PATENT ASSIGNMENT AGREEMENT (this "Assignment"), effective as of March 4, 2009 (the "Effective Date"), is made by and among Idenix Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware, USA ("Idenix USA"), Idenix SARL, a [corporation] organized under the laws of France ("Idenix Frunce"), Idenix (Cayman) Limited, a company organized under the laws of the Cayman Islands ("Idenix Cayman"), the University degli studi di Cagliari, a university organized under the laws of Italy ("University of Cagliar"), the Centre National Del La Recherche Scientifique, a [corporation] organized under the laws of France ("UMS"), and "University of Montpellier II, a [public institution] organized under the laws of France ("UMI"). (Idenix USA, Idenix France, Idenix Cayman, University of Cagliari, CNRS and UM II also may be referred to herein individually as a "party" and collectively as the "parties.")

RECITALS

- A. Idenix France, on behalf of itself and Idenix USA, and CNRS and UM II are parties to that certain Restated and Amended Cooperative Joint Research Agreement dated as of May 7, 2003 (the "French Joint Research Agreement"), pursuant to which each of the parties thereto agreed to jointly own all "Results" (as defined therein) and patents covering such Results.
- B. Idenix France, through its predecessor Novirio SARL, and the University of Cagliari are parties to that certain Co-Operative Antiviral Research Activity Agreement dated January 4, 1999, as amended (the "Italian Joint Research Agreement"), pursuant to which each of them have agreed to jointly own all results obtained from the activities taken thereunder and patents covering such results.
- C. Idenix France, through its predecessor Novirio SARL, and Idenix Cayman, through its contributor Novirio Pharmaceuticals Limited, a corporation formerly organized under the laws of the Cayman Islands, are parties to that certain Research and Development Agreement dated as of August 24, 1998 pursuant to which Idenix Cayman owns all intellectual property rights developed pursuant to "Projects" (as defined therein), except certain of such rights owned by Idenix USA.
- D. The inventors of the United States and foreign patents and patent applications listed on <u>Attachment A</u> assigned their individual rights, titles and interests to their respective employers before the Effective Date.
- E. The parties desire that each of Idenix USA, University of Cagliari, CNRS and UM II (collectively, the "Joint Assignees") each jointly own an equal, undivided right, title and interest in the Jointly Owned Patents (as defined below), subject to the rights and obligations of each Joint Assignee with respect thereto set forth in the French Joint Research Agreement or the Italian Joint Research Agreement, as applicable, through partial assignments by the respective owners as of the Effective Date as necessary to accurately document and record such agreement.

AGREEMENT

NOW, THEREFORE, for good and valuable consideration (including the premises and covenants set forth in the Italian Joint Research Agreement and the French Joint Research Agreement), the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

Each of the parties (each an "Assignor") hereby irrevocably assigns, transfers and sets over to the Joint Assignees all or such portion of such Assignor's right, title and interest in and to the patents and patent applications listed on Attachment A (if any), together with any foreign counterparts or equivalents thereto, existing now or in the future and including, but not limited to, patents of utility, improvement or addition, utility model and appearance and industrial design patents and inventors certificates, as well as divisionals, resisues, continuations (in whole or in part), renewals and extensions of any of the foregoing and any patents that may issue from any of the foregoing or any reissues or reexaminations thereof, and including the inventions described or claimed in the foregoing (all of the foregoing, collectively, "Jointly Owned Patents"), for each Joint Assignee's use and enjoyment, and for the use and enjoyment of their respective successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by each Assignor if this assignment had not been made, in each case such that all of the Joint Assignees hereby jointly own an equal, undivided right, title and interest to all of the Jointly Owned Patents, subject to the terms and conditions of the French Joint Research Agreement and Italian Joint Research Agreement, as applicable.

Each Assignor authorizes and requests the United States Commissioner of Patents and Trademarks and any other similar government authority to record each Joint Assignee as a joint owner of the Jointly Owned Patents and issue any and all patents issued thereon to the Joint Assignees jointly, as assignees collectively of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of the Joint Assignees jointly and their respective successors, assigns or other legal representatives.

Assignors shall provide the Joint Assignees and their respective successors, assigns or other legal representatives, reasonable cooperation and assistance, including the execution and delivery of any and all affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documentation, as may be reasonably required in the implementation, recordation or perfection of this Assignenent. Each of the parties hereby irrevocably appoints Idenix USA and its successors, assigns and other legal representatives as the true and lawful attorney-in-fact on Assignor's and/or Information and the place and stead, to execute any further documents or instruments and do any and all further acts that may be deemed appropriate by Idenix USA and its successors, assigns and other legal representatives to effect the assignments to the Joint Assignee's and their respective successors, assigns and other legal representatives, of the rights, titles and interests made hereby, and to enable such assignments to be recorded and/or perfected in the United States and all foreign countries, and to maintain, issue or extend any Jointly Owned Patents.

Each party is solely responsible for its costs and expenses associated with the execution and delivery of this Assignment. Each Joint Assignee shall be responsible for 25% of all of the out of pocket costs and expenses actually incurred by Idenix USA in connection with the recording or other perfection of this Assignment within the United States and all foreign

countries, including, but not limited to, any recording fees, taxes or other charges payable to any governmental authority or local attorney/agent in connection therewith.

This Assignment may be executed in one or more counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same instrument. This Assignment is governed by the laws of the State of Delaware.

<signature pages follow>

IN WITNESS WHEREOF, each of the parties have executed and delivered this Assignment to effective as of the Effective Date.

Idenix Pharmaceuticals, Inc.

y: **9**

Title: Chat exceeded Office

Idenix SARL

	QL	
Ву:	effect	
Name:	Team Pierre Somme dossi	
Title:	December	

Idenix (Cayman) Limited

	COL 1
Ву:	Chr.
Name: _	Jean Pierre Sontantess,
Title:	Director

Università degli studi di Cagliari

By:

Name: PA SQUALS | MISTRETTA

Title: Rector

IL RETTORE
(Pasquale Mistretta)
(Pasquale Mistretta

- 7 -

C1.1-1695296v3

Centre National	Del	La	Recherch
Scientifique			

By: Directeur de la Politique Industrielle
Name:

Title: Mere L PROLLY

L'Université Montpellier II

TE MONE	Ву:	
12	Name: To Down & HCRIN	
	Title: Prihidente	
OF TROPE	مار	
	S lea	

Attachment A

Jointly Owned Patents

(See attached.)

Attachment A for Patent Assignment Agreement

Sement agreement	Title			2' and 3' Nucleoside Prodrugs for Treating Hepatkis C Virus		2' and 5' Nucleoside Prodrugs for Treating Flaviviridae Infections		2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections		2' and 3' Nucleoside Prodrugs for Treating Playiviridae Infections		2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections	2' and 3' Nucleoside Prodrugs for Treating Flaviviridue Infections		2' and 3' Nuckesside Prodrugs for Treating Flaviviridae Infections		2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections		Z and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
	Filed			6/28/02		6/27/03		12/6/04		12/6/04		5000	12/6/04		12604		12/6/04		12/6/04
•	Serial No.			60/392,351		10/609,298		11/005,471	ĺ	11/005,442	100000	17002,486	11/005,440		11/005,443		11/005,446		11/005,472
	Inventor			Gosselin, G. Sommadossi, JP. Moussa, A. Pierra, C.	Benzaria-Prad, S. Dukhan, D. LaColla, P.	LaColla, P. Sommadossi, JP. Gossetin, G. Storer, R.	0.000	Storer, R. LaColla, P.	Solumboussi, JF.	Gosselin, G. LaColla, P. Sommadossi, JP.	County of	LaColla, P. Sommadossi, JP.	Gosselin, G. LaColla, P.	County C	(Storer, R.) LaColla, A.	Sommadossi, JP.	Gosselin, G. LaColla, A.	Sommadossi, JP.	Sommadossi, JP
	Type Related/ Country		1000	2		11874-015-888 11874-016-888 11874-130-888	CONOL	11874-016-999		CON of 11874-016-999	CONOC	11874-016-999	CON of 11874-016-999	CON of	11874-016-999		CON of 11874-016-999	J. NO.	11874-016-999
	Ref. No.		3112101	PROV		SD 1101	St. 7101	CON	011 2101	CON 2	1017 US	CON 3	CON 4	1017 US	CONS		1017 US CON 6	2117101	CONT
	DOCKET NO.	IDX 1017 Patent Family	11874-016-888			11874-016-999	11874-047-999		11974-046-000	in the second	11874-049-999		11874-050-999	11874-051-999			11874-052-999	11874-053-999	
Jones Dev	CVW	IDX 1017 Ps	417451-888016			417451-999016	417451-999047		117451-999048		417451-999049		417451-999050	417451-999051		117471 000044	750666-154/14	417451-999053	

	2' and 3' Nuchooside Prodrugs for Treating Plavivinidae Infections	1. 2' and 3' Modified Nucleoside Derivatives for Treating Plaviviridae Infections	1. 2' and 3' Modified Nucleonde Derivaives for Treating Flavivindae Infections	1. 2' and 3' Modified Nucleoside Derivaives for Treating Flavivridae Infections	1. 2. and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections	1. 2° and 3' Modified Nucleoside Derivatives for Treating Flavivridae Infections	1'. 2' and 3' Modified Nucleoside Derivatives for Treating Flavivridae Infections	1. 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae nicetions	1. 2. and 3 Modified Nucleoside Derivatives for Treating Flaviviridae Infections	1. 2' and 3' Modified Nuckoside Derivatives for Treating Flavirridae Infections
Title	2' and 3' Nucleo	1', 2' and 3' Mo Infections	1, 2' and 3' Mo Infections	1', 2' and 3' Mo Infections	1', 2' and 3' Mo Infections	1', 2' and 3' Mo Infections	1', 2' and 3' Moc Infections	1'. 2' and 3' Mod Infections	1'.2' and 3' Mox Infections	17.2° and 3° Mod Infections
Filed	12/6/04	6/27/03	6/27/03	6/27/03	6/27/03	6/27/03	6/27/03	627/03	602703	6/27/03
Seria No.	13/005,444	2,490,200	2003263412	537250	PA/s/2004/0 12779	1336-2003	660-2003	2004. \$17162	20050466	2005102096
Inventor	Gosselin, G. LaColla, A. Sommadossi, JP.	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, O.	Sommadossi, JP. LaColla, P. Storer, R. Goszelin, G.	Sommadossi, JP. LaColla, P. Storer, R. Gossedin, G.	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	Sonunadossi, JP. LaColla, P. Storer, R. Gosselin, G.
Type Related/ Country	CON of 11874-016-999	Canada	Australia	New Zoaland	Mexico	aje.	Peru	Japan	Norway	Russian Fod.
Idenix Ref. No.	1017 US CON 8	1017 CA	1017 AU	1017 NZ	1017 MX	1917 CL	1017 PE	1017 JP	ON 1101	1917 RU
Docket No.	11874-054-999	11874-016-001	11874-016-007	11874-016-008	11874-016-009	11874-016-010				11874-016-019
CAM CAM	+00000 1010101 1010101 10101 10101 10101 10101 10101 10101 10101 10101 10101 10101 1	910100-154/14	910000	417451-008016	417451-009016	910010-154/11	417451-011016	000770	41.431-013016	-

Filed Title		89/05 1: 2" and 3" Modified Nucleoside Derivatives for Treating Flaviviridae Infections	6/3003 17.2" and 3" Modified Nucleoside Derivatives for Treating Flaviviridae Infections	_	63003 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections		6/27/03 11/2 and 3 Medified Nucleoside Derivatives for Treating Flaviviridae Infections	62309 17.2° and 3° Modified Nucleoside Derivatives for Treating Flavviridae Infections	63903 11.2 and 3 Modified Nucleoside Derivatives for Treating Flaviviridae	e constant	627/03 17.2 and 3' Modified Nucleoside Derivatives for Treating Flaviviridae. Infections	623/03 1; 2: and 3: Modified Nucleoside Derivatives for Treating Flavvirridae Infections	6/27/03 1:22 and 32 Modified Nucleoside Detinatives for Treating Flavinische Infections
No.	_	0.008300109	1106-2003	-	P030102365 67		P10312271-9 6.7	15960/2003 6/2	T		SP-151-03 6/2 (SP23015)	200407794- 6/2	341/RELNP/ 6/2 2005
Inventor	Commentered 1 D	LaColla, P. Storer, R. Gosselin G	Sommadossi, JP. LaColla. P. Storer. R	Gosselin, G.	Storer, R. Gosselin, G. Imbach, JL. Sommetoeri	Moussa, A.	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	Sorumadossi, JP. LaColla, P. Storer, R. Gosselm, G	Sommadossi, JP. 27,876 LaColla, P.	Storer, R. Gosselin, G.	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	Sommadossi, JP. LaColla, P. Storer, R.
Type Related/	Country Hone Kone		Venczuela	Amenina	annua de			Paraguay	Unguay		Bolive	Singapore	India
Idenix Ref. No.	1017 HK		1017 VE	1017 AR		002101	Š	1017 PY	1017 UY	COLLING	2	1017 SG	NI 7101
Docket No.	11874-016-023		11874-016-025	11874-016-036		11874-016-037		11874-016-039	11874-016-040	11874-016-041		11874-016-055	11874-016-056
Jones Day	417451-023016		417451-025016	417451-036016		417451-037016			+17451-040016	417451-041016			9109071-039019

Docket No.	Ref. No.	Related	Inventor	Serial No.	Filed	Title
	di biol	Country				
	<u></u>	Indonesia	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	W00200500 216	6/27/06	1; 2; and 3; Modified Nuckeoside Derivatives for Teating Flavivindae Infections
	1017 EG	Egypt	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	617/2003	6/28/03	1', 2' and 3' Medified Nucleoside Derivatives for Treating Flaviviridae Infections
	1017 MA	Могоссо	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	28072	627/03	1'. 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
	1017 PH	Philippines	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	1-2005- 500175	627/03	1.2° and 3' Modified Nucleoside Denvaires for Treating Flaviviridae Infections
	1017 TH	Thailand	Sommadossi, JP. LaColla, P. Storer, R. Gosselm, G.	083423	627/03	1.2. md 3. Modified Nucleoside Derivatives for Treating Plaviviridae Infections
	201 CN	Ohina	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	03820690.0	6/27/03	1. 2. and 3. Modified Nucleoside Derivatives for Treating Filaviviridae Infections
1	1017 ZA	South Africa	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	2004/10289	6/27/03	1, 2' and 3' Modified Nucleoside Derivatives for Tealing Flavivridae Infections
		Poland	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	P374792	6/27/03	1, 2 and 3 Modified Nucleoside Derivatives for Treating Flaviviridae Infections
	1017 Y.U	Yugoslavia (former)	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.	P-1141/04	6/27/03	1, 2' and 3' Modified Nuckoside Derivaives for Treating Flavviridae Infections

1017MY Malaysia Sommadosi, 1-4 P12002243 602703 11.7 and 3 Modified Nucleonies Derivatives for Treating Flavoristate Some, R. Same, R.
Cioccin

	wes for Treating Flaviviridae		Treating Hepatitis C Virus	Treating Flaviviridae Infections	Treating Flaviviridae Infections	Treating Flaviviridse Infections	Treating Flaviviridae Infections	Treating Flaviviridae Infections	Treating Flaviviridae Infections	Treating Flaviviridae Infections
Title	1', 2' and 3' Modified Nuckcoside Derivatives for Treating Flaviviridae. Infections		Modified 2' and 3' Nucleoide Produgs for Treams Hepatis C Vinss	Modified Z and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections	Modified 2 and 3 Nucleoside Prodrugs for Treating Flaviviridae Infections	Modified 2 and 3 Nucleoside Prodrugs for Treating Flaviniridae Infections	Modified 2 and 3 Nucleoside Prodrugs for Treating Flaviviridae Infections	Modified 2 and 3 Nucleoside Prodrugs for Treating Flaviviridae Infections	Modified 2' and 3' Nucleonide Prodrugs for Treating Flaviviridae Infections	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
Filed	6/27/03		6/28/02	6/27/03	12/6/04	12/6/04	12/6/04	12/6/04	12/6/04	12/6/04
No.	AP/P/05/003 211		60/392,350	10/608,907	11/005,445	11/005,473	11/005,468	11/005,467	11/005,470	11/005,447
Inventor	Sommadossi, JP. LaColla, P. Storer, R. Gosselin, G.		Storct, R. Gosselin, G. Sommadossi, JP. Moussa, A. LaColla, P.	Storer, R. Gosselin, G. LaColla, P. Sommadossi, JP.	LaColla, P. Storer, R. Gosselin, G. Sommadossi, JP.	LaColla, P. Storer, R. Gosselin, G. Sommadossi, JP.	Storer, R. Gosselin, G. LaColta, P. Sommadossi, JP.	LaColla, P. Storer, R. Gosselin, G. Sommadossi, JP.	LaColle, P. Storer, R. Gosselin, G. Sommadossi, JP.	Storer, R. Gosselin, G. LaColla, P.
Type Related/ Country	ARIPO		PROV	11874-015-888 11874-055-888 11874-130-888	CON of 11874-055-999	CON of 11874-055-999				
Idenix Ref. No.	1017 AP		1018 US PROV	1018 US	1018 US CON 1	IOI8 US CON 2	1018 US CON 3	1018 US CON 4	1018 US CON 5	000 6 000 6
Docket No.	11874-016-262	itent Family	11874-055-888	11874-055-999	1874-056-999	11874-057-999	11874-058-999	11874-059-999	11874-060-999	11874-061-999
CAM	417451-262016	IDX 1018 Patent Family								190000-100111

9

	Modified 2' and 3' Nucleoiske Prodrogs for Treating Flaviviridae infections	Modified 2' and 3' Nucleoside Prodregs for Treating Fluviviridae Infections	Modified 2' and 3' Nucleoside Prodrugs for Treating Flavivaridae Infections	Modified 2' and 3' Nucleoside Prodrugs for Treating Flavivinidae infections	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae infections	Modified 2 and 3 Nucleoside Prodrugs for Treating Flaviviridae Infections	Modified 2 and 3' Nucleonde Prodrugs for Treating Flaviviridae Infections	Modified 2 and 3' Nucleoside Prodrugs for Treating Flavviridae Infections	Modified 2' and 3' Nucleoride Prodrugs for Treating Flaviviridae Infections
Titte	Modifies	Modified	Modified	Modified	Modified	Modified	Modified	Modified	Modified
Filed	12/6/04	12/6/04	80709	6/27/03	6/27/03	6027/03	6/27/03	6/30/03	6/30/03
Scrial No.	11/005,441	11/805,469	12/131,868	2,490,191	2003247084	537663	PA/a/2004/0 12709	1337-2003	00659/2003
Inventor	Storer, R. Gorselin, G. LaColla, P. Sommadoss, JP. LaColla, P. LaColla, P. Greesin, C.		LaColla, P. Storer, R. Gosselin, G. Sommadossi, JP.	LaColla, P. Storer, R. Goszelin, G. Sommadossi, JP.	Storer, R. Gosselin, G. LaColla, P. Sommadossi, JP.	LaColla, P. Storer, R. Gosselin, G. Sommadossi, JP.	LaColla, P. Storer, R. Gosselin, G. Sommadossi, JP.	Storer, R. Gosselin, G. LaColla, P. Sommadossi, JP.	LaColla, P. Storer, R. Gosselin, G. Sommadossi, JP
Type Related/ Country	CON of 11874-055-999	CON of 11874-055-999	DIV of 11874- 055-999	Canada	Australia	New Zealand	Mexico	Onie	Peru
Ref. No.	CON 7	TOUR US CON 8	1018 US DIV	1018 CA	1018 AU	ZN 8101	1018 MX	1018 CL	1018 PE
Docket No.	11874-062-999	1874-063-999	11874-190-999	11874-055-001	11874-055-007	11874-055-008	11874-055-009	11874-055-010	11874-055-011
CAM CAM	41/451-999062	417451-999063	061996-164/14 061996-164/14	417451-001055	417451-007055			41.451-010055	41/451-011055

MA	Y I	- XBe	Inventor	Serial	Filed	Title
	Ref. No.	Country		No.	1	
	df 8101	Japan	LaColla, P. Storer, R. Goszelin, G. Sommadossi, JP.	2004- 517158	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flavviridae Infections
-	ON 8101	Norway	Storer, R. Gosselin, G. LaColla, P. Sommadossi, JP.	20050465	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
	1018 RU	Russian Fed.	Storer, R. Gosselin, G. LaColla, P. Somniadossi, JP	2002102013	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
11874-055-023	1018 11K	Hong Kong	LaColla, P. Storer, R. Gosselin, G. Sommadossi, JP.	05106974.2	\$/12/05	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
	1018 VE	Venezuela	LaColla, P. Storer, R. Gorselin, G. Sommadossi, JP.	1101-2003	6/30/03	Mobified 2' and 3' Nucleoside Prodrugs for Treating Planvinidae Infections
	1018 AR	Argentina	Storer, R. Gosselin, G. LaColla, P. Sonmadossi, JP	P030102366	6/30/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae infections
	1018 BR	Brazil	Storer, R. Gosselin, G. LaColla, P. Sommadossi, JP.	Pi0312286-7	627/03	Modified 2 and 3' Nucleoside Prodrugs for Treating Flavinirise Infections
	74 8101	Paraguay	Storer, R. Gosselin, G. LaColla, P. Sommadossi, JP.	15691/2003	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flavwindse Infections
11874-055-040	VO 8101	Unguay	Storer, R. Gosselin, G. LaColla, P. Sommadossi, JP.	27.875	6/30/03	Modified 2' and 3' Nucleonide Prodrugs for Treating Flaviviridae Infections

Dreator Serial Filed Title	Cosselin, C. SP-19-09 6/1000 Modified 2 and 3 Nucleoside Produky for Treating Flavivride Infections. Cosselin, C. Serias Serias Cosselin, C. Serias Serias Cosselin, C. Serias Cosselin, C	Source R. 200407747 627/83 Medifiel 2 and 3 Nacientie Produce for Treating Flaviviries: Infections Coaceas. C. 200407747 627/83 Infections C. 20040774 627/83 Infections C.	Source R. 24DELNP 647703 Modified F and 3 Nucleoule Produce for Treating Plavvirides Infections Conceiling Con	Source R. W0000000 62780 Modified 2 and 3 Nucleoside Produce for Treating Plavinides Infections Coccient. At Leafulb. P. Sommulation, 4.	South Concession 1. 17,0004 41,02004 Modified 2 and 3 Nielscoide Prodrugs for Treating Flavintides Infections Concession 2. And Child South Sout	South, B. Golffel and S'Nuchouse Produce Fordings Particular Infections Acadists of Testing Particular Infections Sommassis, J.P. Sommassis, J.P. Sommassis, J.P. Sommassis, J.P.	South R. 1-2005- Copesing, C. 500173 Modified Z and 3 Neiceake Produgs for Treating Flavivrides Infections Accounts, C. 500173 Modified Z and 3 Neiceake Produgs for Treating Flavivrides Infections Sommetical, J.P.	South R. 00-124 G-2783 Modified 2 and 3 Nucleoside Produce for Treating Flavorishes Infections Cooperate, A. Calcala, P. Sammedonia, J.,	Sours, R. 042001.7 62700 Modified 2 and 3 Netheolie Produce for Treating Flavorridge Infection Costella. Costella. Somewhater of the Costella Source of Treating Flavorridge Infection Somewhater of the Costella Source of Source
Type Inv	Bolivia Store Goss LaCo Soma	Singapore Store	India Store Goss LaCo Some	Indonesia Store Gossa LaCo Somu	Egypt Gosse LaCo Some		2	Thailand Storer, R. Gossetin, 1. Colla, F. LaColla, F. Sommado	China Storet, R. Gosselin, 9 LaColta, P. Sommado
Idenix Ref. No.	1018 BO	1018 SG	Z. 8.	Q18101	1018 EG			H1 8101	1018 CN
Docket No.	1874-055-041	11874-055-055	11874-055-056	11874-055-076	11874-055-078	11874-055-106	11874-055-117	11874-055-131	11874-055-146
CAM	417451-041055	417451-055065	41/451-050035	417451-076055	47.451-078055		-		41/451-146055

6

Jones Day	Docket No.	Idenix	-	Towns of the last			
CAM		Ref. No.	Related/ Country	HINGHIOL	S S	Filed	Title
417451-227055	11874-055-227	1018 EP		LaColla, P. Storer, R. Gosselin, G. Sommadossi, JP.	03761744.6	6/27/03	Modified 2 and 3 Nucleoside Prodrugs for Treating Flavriridse Infections
41/451-228055	11874-055-228	1018 WO	PCT	LaColla, P. Storer, R. Gosselin, G. Sommadossi, JP.	PCT/IB2003 /003246	6/27/03	Motified 2 and 3 Nucleoside Prodrugs for Treating Flavivridae Infections
41,421-241035	11874-055-24[1018 MY	Malaysia	Storer, R. Gosselin, G. LaColla, P. Sommadossi, JP.	PE0032435	6/27/03	Modified 2' and 3' Nuckeside Prodrugs for Treating Flavorridae infections
\$CD797-15-1	11874-055-262	1018 AP	ARIPO	LaColla, P. Storer, R. Gosselin, G. Sommadossi, JP.	AP/P/2005/0 03212	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
41/451-146144	11874-144-146	1018 CN (DIV)	China	LaColla, P. Storer, R. Gossetin, G. Sommadossi, JP.	2007101933	12/3/07	Modified 2' and 3' Nucleoside Prodrugs for Treating Flavritidae Infections
1031 Pa	IDX 1031 Patent Family						
	11874-026-999	1031 US	11874-016-888	Sommadossi, JP. La Colla, P. Gosselin, G	10/607,909	6027/03	2-C-Methyl-3-O-L-Valine Ester Ribofuranosyl Cyticine for Treatment of Flavruridae Infections
417451-999086	11874-086-999	CON I	CON of 11874-026-999	Sommadossi, J. P. Gosselin, G. LaColla, P.	11/516,928	90/9/6	2-C-Methyl-3-O-L-Valine Ester Ribolutanosyl Cytidine for Treatment of Flavirindae Infections
417451-001026	11874-026-001	1031 CA	Canada	Sommadossi, J. P. La Colla, P. Gosselin, G.	2,489,552	6/27/03	2°C-Methyl-3°O-L-Valine Exter Ribofuranosyl Cytaline for Treament of Flaviviridae Infections
-	118/4-026-007	1031 AU		Sommadossi, JP. La Colla, P. Gosselin, G	2003248748	6/27/03	2*C-Methyl-3*O-L-Valine Ester Ribofurancsyl Cytidine for Treatment of Flavivindae Infections
	200-970-110	20 I NZ	New Zealand	Sommadossi, JP. La Colla, P. Gosselin ,G.	537662	602703	2-C-Methyl-3-O-L-Valine Ester Ribofuranceyl Cyridine for Treatment of Flaviuridae Infections
			-	-	-	_	

Jones Day	Docker No.	Idealia	H		The second second		
CAM		Ref. No.	Related/ Country	Inventor	Serial No.	Filed	Title
417451-009026	11874-026-069	1031 MX	Mexico	Sommadossi, JP. La Colla, P. Gosselm ,G.	PA/s/2004/0 12802	6/27/03	2-C-Methys-3-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-010036	11874-026-010	1031 CL	Chile	Sommadossi, JP. La Colla, P. Gossetin .G.	1338-2003	6/30/03	2-C-Methyl-3-O-L-Vaine Ester Ribofuranosyl Cytique for Treament of Flaviviridae Infections
970110-164714	11874-026-011	1031 PE	Pen	Sommadossi, JP. La Colla, P. Gosselin , G.	000661- 2003	6/30/03	2-C-Methyl-3-O-L-Valine Ester Rholtranosyl Cytidine for Treament of Flaviridae Infections
970710-16	11874-026-012	91.1201	Јярав	Sommadossi, JP. La Colla, P. Gosselin ,G.	2004- 518041	6/27/03	2-C-Methyl-3-O-L-V aline Ester Ribofuranosyl Cytidine for Treatment of Flavivirides Infections
41 /451-01 5026	11874-026-015	ON 1891	Norway	Sommadossi, JP. La Colla, P. Gosselin , G.	20050490	6/27/03	2-C-Methyl-3-O-L-Valine Ester Ribofuranesyl Cyridine for Treatment of Flaviveridae Infections
41.431-019026	11874-026-019	1031 RU	Russian Fed.	Sommadossi, JP. La Colla, P. Gosselin, G.	2005102080	6/27/03	2-C-Methyl-3-Co-L-Valine Ester Ribofuranosyl Cysicine for Treatment of Flaviviridae Infocions
070570	11874-026-023	1031 HK	Hong Kong	Sommadossi, JP. La Colle, P. Gosselm, G.	05106114.3	7/19/03	Z-C-Methyl-3-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
41 /431-023026	11874-026-025	1031 VE	Venezuela	Sommadossi, JP. La Colla, P. Gosselin ,G.	1099-2003	6/30/63	2-C-Methyl-3-C-L-Vaine Ester Ribofuranosyl Cytidine for Treatment of Flavivindae Infections
417451-036026	11874-026-036	1031 AR	Argentma	Sommadossi, JP. La Colla, P. Gosselin , G.	P030102363	6/30/03	2-C-Methyl-3-O-L-Valine Ester Ribofurmosyl Cytiqine for Treament of Flaviviridae Infections
17451-03/026	11874-026-037	1031 BR	Brazil	Sommadorsi, JP. La Colla, P. Gosselin , G.	PI0312278-6	6/27/03	2-C-Methyl-3-O-L-Valine Exter Ribofuranosyl Cytidine for Treatment of Flaviviridee Infections
47.7451-046076	16/4-026-039	1031 PY	Paraguay	Sommadoesi, JP. La Colla, P. Gosselin , G.	15962/2003	6/27/03	2-C-Methyl-3-O-L-Valine Ester Ribolurancey! Cytidine for Treatment of Flaviviridae Infections
	000000000000000000000000000000000000000	1031 UV	Uruguay	Sommadossi, JP. La Colla, P. Gosselin ,G.	27.874	6/30/03	2-C-Methyl-3-O-L-Valine Ester Riboluranosyl Cytidine for Treatment of Flavireidee Infections
				The same of the sa		-	

Filed Title	600003 22-C-Methyl-3-O-L-Valine Ester Ribofurasoy/ Cytóline for Treament of Flavivicidae bufescions	602/03 2-C-Methyl-3-O-L-Value Ester Rhofuranosyl Cytoline for Treatment of Flavinishe Infections	627/03 2'-C-Nethyl-3'-O-L-Vaine Ester Ribofuranosyl Cyndine for Treament of Flaviviridae Infections	627/03 Z-C-Melayl-3-O-L-Value Entr Ribofurnosyl Cytidne for Treatment of Flaviviridae Infections	62703 2*C-Metayst-3*-O-L-Valine Ester Riboluranesyi Cyridine for Treatment of Flaviuridae Infections	627/03 2'-C-Metalyi-3'-O-L-Valine Exter Ribofuranosyl Cytidine for Treatment of Flavvuridae Infections	627/03 2-C-Methyl-3-O-L-Valine Ester Ribofurasoryl Cytidite for Treatment of Flavirutdae Infections	627/03 Z-C-Hethyl-3'-O-L-Valine Ester Ribolumnosyl Cytique for Treatment of Flavivirdee Infections	(03) ZCMethyl-3O.LValine Ester Ribofurances/I Cytique for Treatment of Floviridae Infections	703 2-C-Methyl-3-O-L-Valine Ester Riboliurancoyl Cytidine for Treatment of Flaviviridae Infections	(03) 2-C-Methyl-3-O-L-Valine Ester Ribofuranceyl Cytidine for Treatment of Flavivirdae Infections	703 2-C-Methyl-3-O-L-Valine Ester Ribofuranosyl Cytidiae for Treatment of Flavivirides Infections
Serial No.	SP-230149 6/3	200407793- 6/2	344/DELNP 6/2 /2005	W00200500 6/2 214	616/2003 6/2	28070 6-2	1-2005- 6/2 500172	083422 6/2	03820701 X 6/27/03	2004/10290 6/27/03	P-374781 6/27/03	P-1139/04 6/27/03
Inventor	Sommadossi, JP. La Colla, P. Gosselin, G.	Sommadossi, JP. La Colla, P. Gosselin, G.	Sommadossi, JP. La Colla, P. Gosselin, G.	Sommadossi, JP. La Colla, P. Gosselin ,G.	Sommadossi, JP. La Colla, P. Gosselm .G.	Sommadossi, JP. La Colla, P. Gosselin ,G.	Sommadossi, JP. La Colla, P. Gosselin ,G.	Sommadossi, JP. La Colla, P. Gosselin .G.	Sommadossi, JP. La Colta, P. Gosselin , G.	Sommadossi, JP. La Colla, P. Gosselin, G.	Sommadossi, JP. La Colla, P. Gosselin .G.	Sonmadossi, JP. La Colla, P. Gosselin, G.
Type Related/ Country	Bolivia	Singapore	India	Indonesia	Figypt	Morocco	Philippines	Thailand	China	South Africa	Poland	Yugoslavia (former)
Ref. No.	1031 BO	1031 SG	1691 NI	Ω ISI Ω	1031 EQ	1031 MA	1031 PH	1031 TH	1031 CN	1031 ZA	1031 PL	1031 YU
Docket No.	11874-026-041	11874-026-055	11874-026-056	11874-026-076	11874-026-078	11874-026-106	11874-026-117	11874-026-131	11874-026-146	11874-026-147	11874-026-150	11874-026-159
Jones Day	417451-041026	41./451-055026	417451-056026	417451-076026	41/451-0/8026	4)7451-106026				417451-147026	417451-150026	970401-163711

Daciet No.	-	nutrini 1728 Inventor Serial Filed Titte Ref. No. No. Country Country	103) IL framed Sommadosi, 1-2. 165757 67700 C-C-Methy-37-OL-Vation Else Rubolumnosyl Opision for Treatment of Greening Goodsin, Control of Cont	1031 PK Paissup Sommerbook J.P. 579/2000 6/27/00 7/2-Contribute Distriction Below Ester Rubsharmony Opinities for Treatment of Gooding, Gooding Properties the Internet Section 2012	103) TW Taken Sommebon, 1-P. 931/244 62703 P.C.Melley-V.C.A.Valine Ester Riboltzanosyl Cytidine for Treatment of Goodins. Consultation of Goodins.	1031 KR South Kotts Sommadous, JP. 10-2004- 827/03 Z-C-Anthyl-7-O-L-Valine Ester Ribolusmosyl Cytaline for Treatment of Costains, Cost	1031 VM Vetuam Sommuskossi, J.P. 1-2005- 6/2703 Z-C-Methy-3-C-L-Valine Fater Ribolinanoys) Cytidine for Treatment of Goodsia. Consolia.	1031 OA OAP! Sommadousi, J.P. 1200400343 627383 7-C-Mathyl-7O-L-Value Estet Rhofmanooyi Cyválne for Treatment of Oostala, p. 100400343 (Oostala, p. 10040034)	103) EP UPO Sommakoni, J.P. 103/ki 33 6 6/2700 2-C-Metay-3-O-L-Valine Euer Robolumonyl Cytoline for Treatment of Goodins, O. Goodins, O. Comment of Goodins, O.	1031 WO PCT Sommadosts 1.1.P. PCTNLS300 6.2703) Z-C-Matth/3-O-L-Value Euer Rholumooys/ Cyldine for Treatment of Goostin. G. Locola, P. 1920401	103 IAV Malaysia Sommakowa, J.P. PEDMIZAM 62700 2-C-Manhy 3-C-L-Value Entr Ribofuranoryl Cytolor for Treatment of Government of Government of Construction and Construction and Construction of Construction and Construction	1031 AP ARIPO Summadost, 1.P. APPR00500 627003 Z-C-Mathy-3-O-L-Value Este Rholumooyl Cytidics for Treatment of Gostein 6. 00213 Pervisition Interview Intentions	1031 NZ New Zestand Summakota, J.P. 556288 71200 Z.C-Methyl-2-CL-Vuline Enter Rhofumony Cytisine for Treatment of Gooden at Concessing of Gooden and Concessing of Concessing and Concession and Concessing and Concession and Concessi	1031 SG Singapore Sommadoss, 1.P. 200700648. 17607 2.C.Methol. P.O. Indian
	F		1	 	 	 					1		 	1031 SG Singapore (DIV)
Jones Day CAM	r							-			-			

Jones Day	Docket No.	Ref. No.	Type Related/	Inventor	Serial	Filed	Dite
117451 055005					ģ		
8	118/4-086-056	(Dity)	India	Sommadossi, JP. La Colta, P. Gosselin ,G.	8806/DELN P/2007	11/15/07	2-C-Metryl-3-O-L-Valine Ester Ribofuranceyl Cytidine for Treatment of Flaviundae Infections
41745)-146086	11874-086-146	1031 CN (DIV)	China	Sommadossi, JP. La Colla, P. Gosselin , G.	2006710199	12/19/07	2-C-Methyl-3-O-L-Valine Ester Ribofurancsyl Cytidine for Treatment of Flaviviridae Infections
417451-147086	11874-086-147	1031 ZA (DIV)	South Africa	Sommadossi, JP. La Colla, P. Gosselm , G.	2006/07218	829/06	2-C-Methyl-3-O-L-Valine Ester Ribofuranceyl Cyridine for Treatment of Flavoreidae Infections
417451-178086	11874-086-178	1031 PK (DIV)	Pakistan	Sommadossi, JP. La Colla, P. Gossetin ,G.	5472007	1/20/07	2-C-Methyl-3-O-L-Valine Ester Ribofuranosyl Cytisine for Treament of Flaviviridae Infections
40 Pa	IDX 1040 Patent Family						
417451-888077	11874-077-888	1040 US PROV	PROV	Gosselin, G. Seeta, F. LaColla, P. Storer, R. Dukhan, D.	60/582,182	6/23/04	5-Aza-7-Dezaporine Derivatives for Totaling Plavivindae
417451-999077	11874-077-999	1040 US	11874-077-888	Leroy, F. Gosselin, G. Seela, F. LaColla, P. Storer, R.	11/166,498	623/05	5-Aze-7-Dezapunin Dervalives for Treating Flaviviridae
417451-001077	11874-077-001	1940 CA	Canada	Gosella, C. Seela, F. LaColla, P. Storter, R.	2.571,675	6/23/05	5-Aza-l-Deazquine Derivaiwes for Treating Flavivisidae
417451-007077	11874-077-007	1040 AU	Australia	Leroy, F. Gosselin, G. Socia, F. LaColla, P. Stoer, R. Duidhan, D.	2005256963	673305	5-Aza-7-Dezzaputine Demuires for Treating Flavivirides
				Leroy, F.			

Ì	Serial Filed Title	552612 62305 5.47x.7.December 2	TOTAL			006.0 6/23/05	_				2007- 6/23/05 5-Aza-7-Deazapurine Denyatives for Treating Electricities					20070340 623.05 5-Aza-7-Denzapunne Derivatives for Treating Flavouridae				2007102281 6/23/05 S-A22-7-Destanning Designation	Septimination of the state of t				F10312360-7 6/23/05 S-Aza-7-Deazapuine Derivatives for Treating Flavivinds					SOLEGA	200608949- 6/23/05 5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
Inventor		Ö	Socia, F. LaColla, P.	Storer, R.	Dukhan, D.	Gosselin, G. P		LaColla, P.	Dukhan D	croy. F.	Gosselin, G. 2	_	lover, R.	Dulchan, D.	1		LaColla, P.	Storer, R.	ukhan, D.	Gosselm, G. 20	Scela, F.	Storer R.	Dukhan, D.	Corrolin C	_	Colla, P.	Slorer, R.	Dukhan, D.	Gostelia G		
The	Related/ Country	New Zealand				Mexico					Japan				Noonay			9,6		Russian Fed.	^-	3.5		Brazil			<u>s</u>	۵.	Singapore		
Ideniy	Ref. No.	1040 NZ	-			1040 MX					ar Ora				ON 010					1040 RU				1040 BR					1040 SG		
Docket No.		11874-077-008				118/4-077-009				11876.073.013	710/10/10/1				11874-077-015					610-4-05-2018	-			11874-077-037					11874-077-055		
Jones Day	-	417451-008077		_	417161 000032					417451-012077	_				417451-015077		-		- PEOPLO 1945 IL				_	417451-037077					417451-055077		

		3			,	 I												<u> </u>									
*****	3777	5-Aza-7-Deazapurine Derivativos for Treating Flaviviridae			5-Aza-7-Deazapurine Denvatives for Treating Flaviviridas				5-Aza-7-Deazapurine Derivatives for Traating Flaurinidas				5-Aza-7-Deazapurine Derivatives for Treating Flaviorindas	Pillian Pillian			5-Aza-7-Deazaputite Derivatives for Travers Floring	THE REAL PROPERTY AND ADDRESS OF THE PARTY AND			5-Aza-7-Dearmounte Decimal	Service Consulted for Realing Flavourida				2-Aza-7-Deazapurine Derivatives for Treating Flaviviridae	
P. S.		6/23/05			6/23/05				6/23/05				6/23/05				6/23/05				673305				30007		
Seriol	Ŋ.	470/DELNP /2007			PCT1254/20	3			2005800257	ř			P-2006/0684				180200				10-2007-	7001047			7 10087730		
Inventor		Gosselin, G. Seela, F.	Storer, R. Duthan D	Leroy, F.	Gosselin, G. Seela F.	LaColla, P	Dukhan, D.	Leroy, F.	Gosselin, G.	LaCotta, P.	Storer, R.	Leroy, F.	Gosselln, G. Secia F	LaCotte P	Storer, R.	Lenv F	Gosselin, G.	LaColla P	Storer, R. Dukhan D	Leroy, F	Gosselin, G.	LaColla P.	Storer, R.	Dukhan, D.	Gosselia, G.	Soels, F.	Storer, R.
Type	Related/ Country	India			della				Chora				Yugoslavia (former)				israel				South Korea				EPO		
Idenix	Ref. No.	N 040 I		03 0701	3			1000	5				2 8				1040			0.000	_				1040 EP		
Docket No.		11874-077-056		11874-077-078				11874-077-146				11074 055 154	¥61-1/0			1001	8C1-//0-4/91			11874-077,187	•			1	11874-077-227		
Jones Day		//Docu-10-1/1-		417451-078077				417451-146077				417451-154077				417451-148077				417451-187077		-		417451.337033			

		5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae						John Floring Denyatives for Treating Flaviviridae					-
Title		5-Aza-7-					S.A. 7	-		_			
Filed		6/23/05				_	6/23/05						
Serial No.	- Contractor	/002768 6/23/05					200700649 6/23/05						
Inventor	Goeralin G	Socia F.	LaColla, P.	Storer, R.	Dukhan, D.	Leny, F.	Gosselin, G.	Seela, F.	LaColla, P.	Storer, R.	Dukhan, D.	Leroy, F.	
Type Related/ Country	RT						Ukraine						
Idenix Ref. No.	1040 WO						43000						
Docket No.	11874-077-228					1874-077,344							
 CAM	417451-228077					417451-255077				_			